Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia.
Biomarker
COVID-19
Immunity
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
07
10
2021
revised:
16
02
2022
accepted:
19
02
2022
pubmed:
2
3
2022
medline:
16
3
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
SARS-CoV-2 is the cause of worldwide COVID-19, which severity has been linked to the immune and inflammatory response. Here, we investigate Torquetenovirus (TTV) DNA load - a marker reflecting the intensity of the overall immune response - as well as SARS-CoV-2 RNAemia and IgM/IgG antibodies in COVID-19-positive patients. Two hundred and fifteen COVID-19-positive patients were enrolled, including 87 severe cases and 128 mild-moderate cases. SARS-CoV-2 RNAemia and IgM/IgG antibodies, as well as TTV DNA loads, were measured on longitudinal plasma samples. The rate of severe cases was higher in patients with low TTV DNA load in plasma considering a threshold of 700 copies/mL. In severe patients, SARS-CoV-2 RNAemia positivity rates were higher than those in mild-moderate cases at any timepoint. When combined, TTV DNA load and SARS-CoV-2 RNAemia allowed to predict the outcome of COVID-19 infection, with a higher risk (HR=12.4) of ICU admission in patients with low TTV DNA load and positive SARS-CoV-2 RNAemia. TTV DNA load and SARS-CoV-2 RNAemia may be effective, non-invasive markers reflecting disease severity and poor outcome that could be conveniently measured in a clinical laboratory setting, as soon as COVID-19 diagnosis is made.
Identifiants
pubmed: 35227970
pii: S1386-6532(22)00056-7
doi: 10.1016/j.jcv.2022.105120
pmc: PMC8861125
pii:
doi:
Substances chimiques
Antibodies, Viral
0
RNA, Viral
0
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105120Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Références
Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-1474
pubmed: 32818235
Clin Microbiol Infect. 2016 Jul;22(7):589-93
pubmed: 27093875
J Infect Dis. 2018 Sep 8;218(8):1191-1199
pubmed: 30007341
J Infect. 2019 Jul;79(1):56-60
pubmed: 31100359
Lab Chip. 2020 Jun 21;20(12):2075-2085
pubmed: 32490853
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Age (Dordr). 2014;36(5):9716
pubmed: 25284090
Clin Infect Dis. 2022 May 3;74(9):1525-1533
pubmed: 34374761
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):545-550
pubmed: 32379729
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Emerg Microbes Infect. 2020 Dec;9(1):469-473
pubmed: 32102625
J Med Virol. 2020 Oct;92(10):1789-1790
pubmed: 32297995
J Heart Lung Transplant. 2017 Mar;36(3):366-368
pubmed: 27876413
Am J Transplant. 2019 May;19(5):1599-1601
pubmed: 30468687
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
PLoS One. 2021 Jul 13;16(7):e0254640
pubmed: 34255796
J Clin Virol. 2018 Aug;105:118-127
pubmed: 29957546
Diagn Microbiol Infect Dis. 2020 Dec;98(4):115181
pubmed: 32957073
Anaesth Crit Care Pain Med. 2020 Dec;39(6):731-732
pubmed: 33010489
Clin Infect Dis. 2022 Jan 29;74(2):218-226
pubmed: 33949665
J Med Virol. 2022 Jan;94(1):147-153
pubmed: 34411312